Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Only the indication (partial-onset seizures) and general availability of oral/IV formulations are broadly consistent with the provided label excerpts. Most other claims (mechanism, effectiveness details, side effects, boxed warning for angioedema, specific rash/allergy stopping guidance, and several adverse reaction statements) are not supported by the supplied prescribing information text and therefore cannot be verified; some relate to labeling content but are missing key label-accurate context (e.g., boxed warning status).
Category Scores
Accurate Statements
Lacosamide is prescribed for partial-onset seizures.
Section 1.1: MOTPOLY XR indicated for treatment of partial-onset seizures in adults and pediatric patients weighing at least 50 kg.
Lacosamide has reported serious adverse reactions including cardiac rhythm and conduction abnormalities and DRESS/multiorgan hypersensitivity.
Sections 5.3 and 5.6 are referenced; Section 6 lists serious adverse reactions including Dizziness and Ataxia, Cardiac Rhythm and Conduction Abnormalities, and DRESS/Multiorgan Hypersensitivity.
Unsupported Statements
Lacosamide works by selectively targeting specific sodium channels in the brain.
The provided label text states: enhances slow inactivation of voltage-gated sodium channels, but does not state 'selectively targeting specific sodium channels' in the way claimed.
By blocking these channels, lacosamide reduces the frequency and severity of seizures.
Provided label excerpt describes stabilization and inhibition of repetitive neuronal firing; it does not state 'blocking these channels' or 'reduces severity' using that phrasing.
Lacosamide was first approved by the FDA in 2008.
No FDA approval date is provided in the supplied excerpts.
Lacosamide has been shown to be effective in reducing seizure frequency in patients with partial-onset seizures.
Effectiveness is described for immediate-release monotherapy and adjunctive therapy, but the statement is not tied to the specific provided study details or endpoints in the excerpt.
The most common side effects of lacosamide include dizziness, headache, fatigue, nausea, vomiting, diarrhea, abdominal pain.
The supplied label excerpts do not list 'most common' adverse reactions or those specific frequencies/contents.
Lacosamide can cause skin rash.
Postmarketing experience lists 'rash' as an identified adverse reaction, but the label excerpt does not establish this as a general 'can cause' without context; however, rash is indeed listed—this statement is only partially supported. Scored instead under adverse reactions category as not fully verifiable against 'most common' framing.
Lacosamide can cause allergic reactions.
The label excerpt includes hypersensitivity/DRESS and mentions facial swelling within DRESS description, but does not broadly state 'allergic reactions' as such.
Lacosamide can cause increased heart rate and changes in blood pressure.
Not supported by the supplied excerpts.
Lacosamide can cause confusion and memory problems.
Psychiatric disorders including hallucination are listed in postmarketing, but confusion and memory problems are not included in the supplied excerpts.
Lacosamide has a boxed warning for the risk of angioedema.
The supplied prescribing information excerpts do not show a boxed warning section or boxed warning statement.
Angioedema is a severe allergic reaction that can cause swelling of the face, lips, tongue, and throat.
Postmarketing lists angioedema as an adverse reaction, but the supplied excerpts do not describe specific swelling locations in that level of detail.
If a rash occurs while taking lacosamide, it should be reported to a doctor immediately.
The supplied excerpt does instruct evaluation/discontinuation for DRESS signs/symptoms, but does not provide a general rash reporting instruction for all rashes.
The response described for experiencing a rash while taking lacosamide includes stopping the medication immediately.
For DRESS/multiorgan hypersensitivity, the label states MOTPOLY XR should be discontinued if an alternative etiology cannot be established; it does not provide a blanket immediate stop instruction for any rash.
The response described... includes seeking medical attention if the rash is severe.
Not stated in the supplied excerpts.
The response described... includes seeking medical attention if there are symptoms such as difficulty breathing or swallowing.
Not stated in the supplied excerpts.
A recommendation is given not to stop taking lacosamide without consulting a doctor.
Not supported by the supplied excerpts; the DRESS excerpt indicates discontinuation when criteria are met, but does not provide this specific counseling recommendation.
Side effects should be reported to a doctor immediately.
Not supported by supplied excerpts.
Contradictions
Low
AI Statement
Lacosamide has a boxed warning for the risk of angioedema.
Label Reference
Provided excerpts include warnings and precautions (Sections 5.3, 5.6) and adverse reactions (Section 6) but do not include any boxed warning text.
Important Omissions
Mechanism of action in the label excerpt emphasizes enhancement of slow inactivation of voltage-gated sodium channels and stabilization of hyperexcitable neuronal membranes; the response’s mechanism framing and wording are not label-accurate enough to verify.
Importance:
Moderate
For warnings, the label excerpt specifically addresses DRESS/multiorgan hypersensitivity with evaluation immediately for signs/symptoms and discontinuation if alternative etiology cannot be established; the response provides rash/angioedema guidance without matching the label’s DRESS framework and discontinuation criteria.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several rash/angioedema counseling statements and the claim of a boxed warning are not supported by the supplied label excerpts and could mislead regarding urgency/decision criteria. However, the provided label does support serious hypersensitivity evaluation/discontinuation in specific circumstances (DRESS).
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Many safety/counseling and adverse reaction claims (including 'boxed warning for angioedema' and specific rash/stop/medical attention instructions) are not supported by the supplied prescribing information excerpts.
Suggested Improvement
Restrict statements to information explicitly present in the provided label text (e.g., indication for partial-onset seizures; DRESS/multiorgan hypersensitivity evaluation/discontinuation guidance; listed serious adverse reaction categories and postmarketing inclusion of rash/angioedema) and avoid asserting boxed-warning status, 'most common' adverse events, or generalized rash/stop instructions not supported in the excerpts.